Prothena to Report First Quarter 2021 Financial Results on May 11th

Rhea-AI Summary

Prothena Corporation plc (NASDAQ:PRTA) will report its Q1 2021 financial results on May 11, 2021, after U.S. market close. Consistent with past practices, the company will not host a conference call for this release. Prothena specializes in treating rare peripheral amyloid and neurodegenerative diseases, leveraging decades of research in protein dysregulation. Its pipeline includes candidates targeting AL amyloidosis, ATTR amyloidosis, Alzheimer's, Parkinson's, and other related diseases.

Positive

• Pipeline includes investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases.
• Expertise in protein dysregulation supports potential advancements in treatment.

Negative

• None.

DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 11.

About Prothena

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:

Media & Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

FAQ

When will Prothena report its Q1 2021 financial results?

Prothena will report its Q1 2021 financial results on May 11, 2021, after the close of U.S. financial markets.

Will there be a conference call for Prothena's Q1 2021 earnings release?

No, Prothena will not conduct a conference call in conjunction with the Q1 2021 earnings release.

What diseases does Prothena focus on in its pipeline?

Prothena focuses on rare peripheral amyloid and neurodegenerative diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, and Parkinson's disease.